Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

delivered double digit growth including VYVANSE(up 21% to $299 million), LIALDA/MEZAVANT (up 36% to $142 million), ELAPRASE® (up 17% to $129 million), VPRIV® (up 17% to $88 million), INTUNIV® (up 17% to $81 million) and FIRAZYR(up 107% to $63 million). LIALDA/MEZAVANTsales in Q3 2013 were particularly strong, primarily due to growth in US market share.

Growth in total product sales was moderated by DERMAGRAFT® (down 29% to $24 million), ADDERALL XR® (down 20% to $81 million) and REPLAGAL® (down 11% to $109 million). REPLAGAL product sales continue to be impacted by the return of competition to the Fabry market.

  • Total revenues were up 12% to $1,237 million (Q3 2012: $1,100 million) as the growth in product sales was partially offset by lower royalties.
  • On a Non GAAP basis:

Operating income was up 30% to $422 million (Q3 2012: $325 million), as total operating costs in Q3 2013 increased at a lower rate (up 5%) than total revenues (up 12%) demonstrating our focus on delivering efficient growth. Research and Development expenditure was up 2% and Selling, General and Administrative expenditure was up 1%.

On a US GAAP basis:

Operating income was up 25% to $341 million (Q3 2012: $273 million), a lower rate of increase than on a Non GAAP basis as Q3 2013 included higher acquisition and integration costs as compared to Q3 2012 and reorganization costs of $14 million not incurred in Q3 2012. Research and Development expenditure was up 2% and Selling, General and Administrative expenditure was up 1%.

  • Non GAAP diluted earnings per American Depository Share ("ADS") increased 30% to $1.77 (Q3 2012: $1.36) primarily due to higher Non GAAP operating income.

On
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... September 30, 2014 New applications of ... that have evolved in nature over millennia are featured ... materials for applications in biophotonics in the October ... The journal is published by SPIE, the international society ... Several of the peer-reviewed articles are accessible via open ...
(Date:10/1/2014)... 01, 2014 The U.S. Department of ... Illinois University Edwardsville as part of the Trade Adjustment ... funding is co-administered by the Department of Labor and ... of Labor Thomas E. Perez and Secretary of Education ... job-driven training grants to nearly 270 colleges across the ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
(Date:9/30/2014)... Sept. 30, 2014 Report Details ... highest potential revenues Do you want to find ... you revenue predictions for those biological drugs from ... you find financial data, R&D trends, opportunities and ... sales forecasts to 2024 at overall world market, ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... Dec. 13 BioMed Realty Trust, Inc.,(NYSE: BMR ... to its,board of directors, increasing the board to eight ... real estate industry, with a breadth of,ability and experience ... real estate projects. We believe that,Rick,s contributions to our ...
... new validation studies,were published during 2007 on the ... number of studies published to 65., "This ... interest from US and,European institutes" said Gary Zamler, ... academic medical institutions and teaching hospitals,have completed studies ...
... retired $12.83 million in existing current 2008 convertible notes, and extended the ... ... convertible notes, SEATTLE, Dec. 13 Cell Therapeutics, Inc.,("CTI" or the ... of its new 5.75% Convertible Senior,Notes (the "New Notes") due 2011 and ...
Cached Biology Technology:BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 32007 a "Record Year" for Successful Validation Studies of Simbionix Simulators 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3
(Date:10/1/2014)... TURKU, Finland , October 1, 2014 /PRNewswire/ ... breaking through in the life science field  ... detection technologies come and go over the years. ... golden standard. Photon upconversion is a novel detection ... during recent years. Now, finally, this technology is ...
(Date:9/30/2014)... is published today in the first authoritative scientific study ... on both sides of the grouse moor management debate. ... the Ecohydrology of River basins) project has shown that ... support red grouse populations for gun sports, has significant ... properties, river water chemistry and river ecology. , A ...
(Date:9/30/2014)... conducted by the Ocean Health Index rates the ... overall health. In addition, for the first time, ... ocean regions beyond national jurisdiction (high-seas areas) ... safeguarding biodiversity and providing sustainable food sources. , ... a partnership led by scientists from UC Santa ...
Breaking Biology News(10 mins):First-of-a-kind Solution for Utilizing Photon Upconversion 2Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3
... For those living with gastrointestinal disorders, such as ulcers or ... or dietary changes. But what if one day treatment meant ... free of inflamed or diseased tissues? That is ... Institute of Technology (MIT) are hoping their new study findings ...
... The winners of NERC,s inaugural short article and photography ... London this evening. The winning essay, by Laura ... excitement she felt during a recent research voyage when ... black smoke across her monitoring screens. These are underwater ...
... the 20th International AIDS Conference (AIDS 2014) to be ... today announced 19 major plenary presentations, focusing on the primary ... sessions will open each day of the conference, which is ... 200 countries. "We are excited to have such ...
Cached Biology News:Manufacturing a new gut to treat GI diseases 2NERC announces the winner of its first photo and essay competition 2NERC announces the winner of its first photo and essay competition 320th International AIDS Conference (AIDS 2014) plenary speakers announced 220th International AIDS Conference (AIDS 2014) plenary speakers announced 3
... cDNA normalization is essential for hunting ... high-throughput approaches, such as EST sequencing ... normalization methods are not well suited ... The Evrogen TRIMMER kit, though, is ...
... Tecan has 20 years of expertise in ... and still offers the most powerful systems ... up to 40 000 in-microplate tests requiring ... integration of different modules (such as worktable ...
... 6 delivers enhanced statistics and statistical ... quality improvement managers. As an accepted ... 6 simplifies statistics for novice users ... by experts. It offers a powerful ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Biology Products: